Next Article in Journal
Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B
Next Article in Special Issue
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
Previous Article in Journal
Loss of PTEN in Fallopian Tube Epithelium Results in Multicellular Tumor Spheroid Formation and Metastasis to the Ovary
Previous Article in Special Issue
Atypical Histiocytoid Cells and Multinucleated Giant Cells in Fine-Needle Aspiration Cytology of the Thyroid Predict Lymph Node Metastasis of Papillary Thyroid Carcinoma
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle

MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma

Institute of Pathology, University of Bern, Murtenstrasse 31, CH 3008 Bern, Switzerland
Department of Pathology and Molecular Pathology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
Institute of Surgical Pathology, Stadtspital Triemli, Birmensdorferstr. 497, 8063 Zürich, Switzerland
Department of BioMedical Research, University of Bern, Murtenstrasse 31, CH 3008 Bern, Switzerland
Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Author to whom correspondence should be addressed.
Cancers 2019, 11(6), 885;
Received: 17 May 2019 / Revised: 13 June 2019 / Accepted: 14 June 2019 / Published: 25 June 2019
(This article belongs to the Special Issue Thyroid Cancer)
PDF [2280 KB, uploaded 25 June 2019]


Five percent of papillary thyroid carcinomas (PTC) show an adverse clinical outcome (ACO). The tall cell variant of papillary thyroid carcinomas (TCV) is a good predictor of an ACO, however, the identification of tall-cells is subjective. Micro RNAs are short non-coding ribonucleic acids (miRNA). Their expression in PTC could be a powerful, more objective predictor of prognosis. Methods: Forty-four PTC underwent miRNA profiling, twenty-four of them were TCV. The miRNA dataset was validated by analysis of expression of known target proteins (vascular endothelial growth factor (VEGF) and phosphatase and tensin homolog (PTEN)) in 125 patients including 48 TCV and 57 with an ACO. Results: One hundred and forty-nine miRNAs were significantly associated with an ACO, seventy-one of them with TC-morphology. Twenty-two miRNAs were identified as targets for VEGF and thirty-two as targets for PTEN. In univariate and multivariable analysis, reduced expression of PTEN and an increased expression of VEGF were associated with shorter relapse free survival. A classifier, including TC-morphology, pT-stage, VEGF, and PTEN, predicted relapse with an 80% accuracy. Conclusions: Some miRNAs predict outcome in PTC and are involved in TC-morphology in PTC. These miRNAs may serve as more objective indicators of an ACO than tall cell morphology. PTEN and VEGF protein expression are prognostically relevant and are at least partially regulated by miRNAs. View Full-Text
Keywords: thyroid carcinoma; miRNA; PTEN; VEGF; prognosis; tall cell; TERT thyroid carcinoma; miRNA; PTEN; VEGF; prognosis; tall cell; TERT

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Boos, L.A.; Schmitt, A.; Moch, H.; Komminoth, P.; Simillion, C.; Marinoni, I.; Nikiforov, Y.E.; Nikiforova, M.N.; Perren, A.; Dettmer, M.S. MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma. Cancers 2019, 11, 885.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top